CytomX Therapeutics (CTMX) Shares Outstanding (2014 - 2026)

CytomX Therapeutics' Shares Outstanding (Entity) history runs 12 years deep, the most recent figure standing at $177.3 million for Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 119.88% year-over-year to $177.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $177.3 million (up 119.88% YoY) and the FY2025 annual result came in at $137.9 million, up 72.2% from the prior year.
• Shares Outstanding (Entity) was $177.3 million for Q1 2026 at CytomX Therapeutics, up from $137.9 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $177.3 million in Q1 2026 and bottomed at $65.4 million in Q1 2022.
• A 5-year average of $90.8 million and a median of $78.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2025 — Shares Outstanding (Entity) declined 1.72% — and 2026, when it surged 119.88%.
• CytomX Therapeutics' Shares Outstanding (Entity) stood at $66.2 million in 2022, then grew by 1.63% to $67.3 million in 2023, then grew by 19.0% to $80.1 million in 2024, then surged by 72.2% to $137.9 million in 2025, then advanced by 28.52% to $177.3 million in 2026.
• Business Quant data shows CTMX's Shares Outstanding (Entity) at $177.3 million in Q1 2026, $137.9 million in Q4 2025, and $169.4 million in Q3 2025.